Benefits

Allows topical delivery of drugs requiring frequent or continuous dosing to the mouth, pharynx and esophagus.

Founders

SynAgile was founded by highly successful serial inventor-entrepreneurs Adam Heller (CSO) and Ephraim Heller (CEO). The father-son team have over 300 patents (most in use) and a track record which includes the founding of AngioScore (sold for $235 million) and TheraSense (which went public and was later sold for $1.2 billion). Adam Heller is also a coinventor of the first commercialized lithium thionyl chloride battery and a recipient of the US National Medal of Technology and Innovation, the highest technology honor in the United States.

The SynAgile founding team began developing OraFuse after seeing an opportunity to improve patients’ quality of life via a new class of drug delivery devices.

News

SynAgile Corporation Announces Closing of $10.4M of Financing

August 24th, 2017

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse® technology platform, today announced the closing of a $10.4 million round of equity investment.

83-year-old invents Parkinson's "Retainer" to deliver Oral Levodopa

March 2nd, 2017

“I would love to see the device widely used by people, while I’m still alive,” says Dr Adam Heller. The 83-year-old research professor at the University of Texas, US, who has more than 260 US patents...

SynAgile Corporation Announces Positive Phase 2A Results

October 8th, 2015

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse® intraoral technology platform, today announced positive results from a proof-of-concept...